Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.
Sodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause death), and renal disease (delay the onset of dialysis) regardless of diabetic status. The consistent cardiorenal benefits observed in major landmark trials have resulted in the rapid adoption of SGLT2i therapy not only in diabetes guidelines but also cardiovascular and renal guidelines.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）是一类最初用于降低糖尿病患者血糖的药物。然而，最近的试验表明它们还有其他有益作用。使用 PUBMED 搜索对 2015 年至 2022 年期间涉及 SGLT2i 药物的主要临床试验进行了回顾。最近的主要 SGLT2i 里程碑试验表明，无论糖尿病患者的状况如何，SGLT2i 药物对心血管疾病（降低主要不良心血管事件（心脏病发作、中风、心血管死亡）、心力衰竭住院、全因死亡）和肾脏疾病（延缓透析开始）均有益处。主要里程碑试验中观察到的一致的心脏肾脏获益促使 SGLT2i 治疗不仅在糖尿病指南中，而且在心血管和肾脏指南中得到了迅速采用。
